Playback speed
10 seconds
ASH 2023 Insights: "Dual Targeting of SLAMF-7 and CD38 - A Ph2 Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone in R/R MM"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Binod Dhakal
By
Insights from 2023 ASH Annual Meeting
FEATURING
Binod Dhakal
393 views
December 21, 2023
Login to view comments.
Click here to Login